Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nITRo: Nal-IRI + 5-FU/LV + Oxaliplatin in Resectable Pancreatic Cancer
NCT03528785Phase 2Unknown
- Sponsor
- Centro Ricerche Cliniche di Verona Srl
- Start
- Mar 2018
- Primary completion
- Nov 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by Centro Ricerche Cliniche di Verona Srl. Status: unknown.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03528785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528785.